Table 1.
Induction chemotherapy followed by chemoradiotherapy for locally advanced sinonasal undifferentiated carcinoma
| Ref. | Year | n | T Stage (T3/4) | N Stage (N0/1/2) | Induction chemotherapy (cycle, regimen) | Chemoradiotherapy (radiation dose, regimen) | ENI | MST1 (mo, range) |
| Musy et al[11] | 2002 | 5 | NS2 | NS | 3, CAV/EP | 55-63 Gy, NS | - | 9 (4-114) |
| Rischin et al[12] | 2004 | 7 | 0/7 | 4/1/2 | 3, FC/FP | 50-60 Gy, CBDCA/CDDP | + | 21 (5-51) |
| Yoshida et al[16] | 2008 | 1 | 0/1 | 0/0/1 | NS, EP | 72 Gy, CDDP | + | 41 |
| Mourad et al[14] | 2013 | 3 | 0/3 | 3/0/0 | 2-3, CDDP/FP/TPF | 3DCRT/IMRT of 60-70 Gy, CDDP3 | + | 27 (16-28) |
| Ansari et al[22] | 2013 | 1 | 0/1 | 0/0/1 | 3, EAP | 60 Gy, CBDCA | - | 16 |
| Gray et al[2] | 2015 | 3 | 0/3 | 2/0/1 | NS, EC/EP | PB of 70 CGE, EC/EP | + | 34 (32-58) |
| Zielinski et al[15] | 2016 | 1 | 0/1 | 0/1/0 | 6, TPF | 60 Gy, CDDP | NS | 17 |
| Bhasker et al[21] | 2017 | 5 | NS | NS | 2, EP/FP/TC | 3DCRT of 70 Gy, CDDP | + | 6 (2.4-34.2) |
| Sienna et al[23] | 2018 | 1 | 0/1 | 0/0/1 | 3, CDDP | 50 Gy, CDDP | - | 17 |
| Our cases | 2 | 0/2 | 0/0/0 | 3, TPF | IMRT of 70 Gy, CDDP | - | 44 | |
MST represents the duration of survival among the patients receiving induction chemotherapy and chemoradiotherapy.
All patients were classified as Kadish C.
Part of patients received CDDP concomitantly with irradiation. CAV: Cyclophosphamide, doxorubicin and vincristine; CBDCA: Carboplatin; CDDP: Cisplatin; CGE: Cobalt-gray equivalents; EAP: Etoposide, doxorubicin and cisplatin; EC: Etoposide and carboplatin; ENI: Elective nodal irradiation; EP: Etoposide and cisplatin; FC: Fluorouracil and carboplatin; FP: Fluorouracil and cisplatin; IMRT: Intensity-modulated radiotherapy; MST: Median survival time; NS: Not specified; PB: Proton beam radiation; TC: Paclitaxel and carboplatin; TPF: Docetaxel, cisplatin and fluorouracil; 3DCRT: 3-dimensional conformal radiotherapy.